Form 4: Kathleen Sebelius Reports Humacyte Stock Transaction

Director Kathleen Sebelius reported a transaction involving Humacyte, Inc. common stock on May 19, 2026.

Summary

• Director Kathleen Sebelius reported a transaction on May 19, 2026, involving Humacyte, Inc. (HUMA) common stock.
• Sebelius acquired 56,818 shares of common stock at a price of $0.88 per share.
• Following this transaction, Sebelius beneficially owns 148,025 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction without providing new financial or strategic information.

Positives

• Director Kathleen Sebelius acquired a significant number of shares, indicating potential confidence in the company.
• The acquisition was made at a price of $0.88 per share, which could be seen as a favorable entry point.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and provide transparency into the holdings and activities of company directors and officers. This filing indicates a purchase of Humacyte, Inc. stock by a director.

Stakeholder Impact

• Shareholders may view the director's purchase positively, potentially signaling confidence in the company's future prospects.

Key Dates

Keywords

Humacyte, HUMA, Form 4, SEC Filing, Insider Transaction, Director, Common Stock, Beneficial Ownership